Holen Sie sich die Stockscreener-App
21.44
0.80%
0.17
Handel nachbörslich:
21.22
-0.22
-1.03%
Schlusskurs vom Vortag:
$21.27
Offen:
$21.27
24-Stunden-Volumen:
1.92M
Relative Volume:
1.31
Marktkapitalisierung:
$2.62B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
18.17
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
+0.23%
1M Leistung:
+2.88%
6M Leistung:
-13.69%
1J Leistung:
-2.06%
1-Tages-Spanne:
$20.95
$21.74
1-Wochen-Bereich:
$20.72
$21.74
52-Wochen-Spanne:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.44 | 2.60B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Using portfolio simulators with Catalyst Pharmaceuticals Inc. included2025 Historical Comparison & Risk Controlled Daily Plans - newser.com
Why global investors buy Catalyst Pharmaceuticals Inc. (CN2) stockWeekly Risk Report & Free AI Powered Buy and Sell Recommendations - newser.com
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference - The Manila Times
Momentum divergence signals in Catalyst Pharmaceuticals Inc. chartJuly 2025 Pullbacks & High Yield Stock Recommendations - newser.com
Is Catalyst Pharmaceuticals Inc. (CN2) stock a buy on weakness2025 Momentum Check & Risk Adjusted Swing Trade Ideas - newser.com
Applying Elliott Wave Theory to Catalyst Pharmaceuticals Inc.Quarterly Portfolio Report & Expert Curated Trade Setups - newser.com
Catalyst Pharmaceuticals (CPRX): Exploring Valuation as Shares Remain Steady and Investors Weigh Long-Term Growth - Yahoo Finance
Can Catalyst Pharmaceuticals Inc. hit a new high this monthEarnings Overview Report & High Return Stock Watch Alerts - newser.com
Will Catalyst Pharmaceuticals Inc. stock split again soon2025 Momentum Check & Daily Stock Momentum Reports - newser.com
What analyst consensus says on Catalyst Pharmaceuticals Inc. stockJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Will Catalyst Pharmaceuticals Inc. (CN2) stock keep high P E multiplesWeekly Loss Report & Consistent Return Investment Signals - newser.com
Is Catalyst Pharmaceuticals Inc. (CN2) stock attractive post correctionPortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Catalyst Pharmaceuticals Inc. recovery potential after sell offWeekly Trade Report & Entry Point Confirmation Alerts - newser.com
What risks investors should watch in Catalyst Pharmaceuticals Inc. stockJuly 2025 Drop Watch & Accurate Intraday Trading Signals - newser.com
Using Bollinger Bands to evaluate Catalyst Pharmaceuticals Inc.Gap Down & Reliable Price Breakout Signals - newser.com
Price momentum metrics for Catalyst Pharmaceuticals Inc. explainedIndex Update & Technical Pattern Based Buy Signals - newser.com
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Will Catalyst Pharmaceuticals Inc. (CN2) stock sustain uptrend momentumBuy Signal & Community Verified Watchlist Alerts - newser.com
Is Catalyst Pharmaceuticals Inc. stock bottoming outWeekly Stock Recap & Low Risk Entry Point Guides - newser.com
Can Catalyst Pharmaceuticals Inc. (CN2) stock surprise with quarterly resultsAnalyst Downgrade & Stock Portfolio Risk Control - newser.com
How rising interest rates impact Catalyst Pharmaceuticals Inc. stockPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Yorktown Management & Research Co Inc Trims Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q3 Earnings Expected to Decline - Yahoo Finance
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):